Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

0001326110-25-000033.txt

ImmunityBio (NASDAQ:IBRX)
Historical Stock Chart
From Feb 2025 to Mar 2025

Click Here for more ImmunityBio Charts.

ImmunityBio (NASDAQ:IBRX)
Historical Stock Chart
From Mar 2024 to Mar 2025

Click Here for more ImmunityBio Charts.

ImmunityBio Inc News

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Monday 3 March 2025 (6 days ago) • Edgar (US Regulatory)

Form 8-K - Current report
Monday 3 March 2025 (6 days ago) • Edgar (US Regulatory)

ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
Monday 3 March 2025 (6 days ago) • Business Wire

ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
Friday 28 February 2025 (1 week ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 26 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 26 February 2025 (2 weeks ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 26 February 2025 (2 weeks ago) • Edgar (US Regulatory)

FDA Authorizes ImmunityBio to Provide Recombinant BCG (rBCG) to Urologists to Address TICE® BCG Shortage
Thursday 20 February 2025 (3 weeks ago) • Business Wire

ImmunityBio Announces UK Medicines and Healthcare Products Regulatory Agency Accepted Marketing Authorization Application for ANKTIVA® for the Treatment of Patients with BCG-unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
Friday 14 February 2025 (3 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 13 February 2025 (4 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Saturday 8 February 2025 (4 weeks ago) • Edgar (US Regulatory)

ImmunityBio Announces Collaboration with BeiGene on Confirmatory Phase 3 Trial of ANKTIVA® and PD-1 Checkpoint Inhibitor Combination in Non-Small Cell Lung Cancer
Thursday 30 January 2025 (1 month ago) • Business Wire

More ImmunityBio Inc News Articles

Gold vs US Dollar

S&P ASX 300 Metals and M...

Verizon Communications

Woodside Petroleum

Australia And New Zealan...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions